Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs

Summary

Novo Nordisk has entered a multi-drug partnership with Orbis Medicines worth up to $1.4B to develop oral macrocycle candidates targeting cardiometabolic diseases and potential weight loss indications. Both Novo and Eli Lilly have previously invested in the biotech.